Omega Diagnostics Share Discussion Threads

[power talker] 07/8/2007 09:19

In for another 100k..

[power talker] 07/8/2007 09:17

Excellent news yesterday..markets missed this one in for 250k ..should double today...Next to know shares in issue this is going to fly.

[smiler 0] 06/8/2007 12:27

I too still hold a few, but you never know may see 3p again when they get back on there feet !!!!!

[guman] 06/8/2007 12:20

the worst share i hold.
bought 100k@2.75 and would be glad to get out @1p.
the other not so good are nta, mph,aur.

[gadg3t] 06/8/2007 09:41

Omega Diagnostics Group PLC
06 August 2007


For release
6 August 2007
Omega Diagnostics

PROPOSALS FOR THE ACQUISITION OF
GENESIS DIAGNOSTICS LIMITED
AND
CAMBRIDGE NUTRITIONAL SCIENCES LIMITED,
PLACING OF 7,333,333 NEW ORDINARY SHARES OF 4p EACH AT 30p PER SHARE,
SHARE CONSOLIDATION,
CAPITAL REORGANISATION
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING


Omega, a medical diagnostic company that produces and sells a wide range of
in-vitro diagnostic test kits, is pleased to announce that it has conditionally
agreed to acquire the entire issued share capital of Genesis Diagnostics Limited
and Cambridge Nutritional Sciences Limited (together 'Genesis-CNS'). The
Acquisition of Genesis-CNS constitutes a reverse take-over under Rule 14 of the
AIM Rules.

Genesis-CNS is a growing, profitable, cash-generative business serving the
clinical diagnostics market. Genesis-CNS supplies test kits to hospital
laboratories in the UK and overseas, via a network of distributors, in 27
countries. Genesis-CNS produces 80 different test kits, plus a line of 24
quality control products, mainly in the areas of autoimmune diseases and food
intolerance as well as providing testing services for food intolerance and some
diseases.

The consideration for the Acquisition is to be satisfied as to £3.2 million
payable in cash on Completion; the issue of Consideration Shares at the Placing
Price not to exceed the lesser of £1.4 million or 29.99 per cent. of the
Enlarged Issued Share Capital; an amount in cash equal to the difference between
the value of the Consideration Shares at the Placing Price and £1.4 million to
be payable one year after completion; deferred consideration payable in cash in
accordance with the Earn Out Calculation; and the issue of a loan note in
respect of £1.1 million.

The Company also announces that it has raised, conditional on Admission, £2.2
million by means of a placing of 7,333,333 New Ordinary Shares at 30p (0.75p
before reorganisation and consolidation) per Placing Share by Teather &
Greenwood in order to provide funds for the Acquisition. A further £1.2 million
of funding for the Acquisition will be provided by a loan from Bank of Scotland.

The Company is also proposing to undertake a Share Consolidation and Capital
Reorganisation, further details of which are set out below.

Completion of the Acquisition, the Placing, the Share Consolidation and the
Capital Reorganisation are subject, amongst other things, to the approval of
Shareholders, which is to be sought at the Extraordinary General Meeting
convened for 11.30am on 30 August 2007 to be held at the offices of Brodies LLP,
at 15 Atholl Crescent, Edinburgh EH3 8HA. The Directors have irrevocably
undertaken to vote in favour of the Resolutions in respect of their own
beneficial shareholdings which amount in aggregate to 37,324,976 Ordinary Shares
(representing approximately 30.29 per cent. of the Ordinary Shares currently in
issue).

The Company has posted an Admission Document to Shareholders along with the
Notice of EGM. Dealings in the Company's Ordinary Shares on AIM are expected to
recommence with immediate effect.

Andrew Shepherd, Chief Executive of the Company commented:

'The acquisition of Genesis-CNS is highly significant as it is our first since
joining AIM in September 2006. Genesis and CNS are growing, profitable and cash
generative businesses operating in the growth markets of Autoimmune Disease and
Food Intolerance testing. They also have proven new technologies which will
strengthen and diversify the Omega product offering.

'We look forward to presenting this enhanced product range to our extensive
distribution network spanning over 100 countries.'

[gadg3t] 06/8/2007 09:40

AIM
06 August 2007

NOTICE

(489)

06/08/2007 7:00am

RESTORATION OF TRADING ON AIM

OMEGA DIAGNOSTICS GROUP PLC



The trading on AIM for the under-mentioned securities was temporarily suspended.
The suspension is lifted from 06/08/2007 7:00am.

[guman] 15/7/2007 21:45

when would trading restart,any idea?

[maestro4] 12/7/2007 13:38

suspension.

[rheiner] 03/7/2007 09:30

Improving potential. Buying these at 1p today could pay off well for those with a bit of patience imo.

[gadg3t] 02/7/2007 17:37

Agree, I think with time will see 3p again with luck !!

[parvez] 02/7/2007 17:30

Also see announcement last week...."1 million new equity (before expenses) raised via a cash placing of 50,000,000 New Ordinary Shares at 2p per share".

You can buy it at half the price today! Once the market wakes up these will be worth much more than 2p. Also strong new managment team...

[gadg3t] 02/7/2007 15:18

As I said befor there products are excellent in the diagnosis of infectious diseases,particularly Syphilis, TB and Dengue Fever,and product range covers a wide application area in over 100 countries . I still think this could do well all be it slow to take off.

[guman] 02/7/2007 14:14

why sudden rise after nearly year's sleep?

[gadg3t] 26/6/2007 20:22

just some of the RNS out today!!! YES AS I SAID end of June and up 12%

Omega Diagnostics Group PLC
26 June 2007



OMEGA DIAGNOSTICS GROUP PLC
('Omega' or the 'Company')



FINAL RESULTS
FOR THE YEAR ENDED 31 MARCH 2007



Omega, a medical diagnostic company that produces and sells a wide range of
in-vitro diagnostic test kits, announces results for the year ended 31 March
2007.

Omega operates in a niche market supplying tests for specific infectious
diseases and other clinical conditions through its distribution network in more
than 100 countries. The infectious diseases include Syphilis, TB, Dengue Fever
and Malaria. All products are designed for use in clinical laboratories and
Rapid Tests are designed for use at the point of care.


Financial Summary:
Year to Year to
31 March 31 March
2007 2006

Revenue 2,032,146 2,143,806
Gross profit 831,489 868,145
Operating (loss)/profit (885,652) 162,661

(Loss)/profit before tax (1,141,225) 197,722



2007 Highlights:



• Acquisition by Quintessentially English plc of Omega Diagnostics Limited

• Change of name from Quintessentially English plc to Omega Diagnostics
Group PLC

• 1 million new equity (before expenses) raised via a cash placing of
50,000,000 New Ordinary Shares at 2p per share

• Appointment of a new management team from Omega Diagnostics Limited:

• David Evans, Non-Executive Chairman;
• Andrew Shepherd, Chief Executive;
• Kieron Harbinson, Finance Director; with
• Michael Gurner continuing as a Non-Executive Director

• European patent grant for Branched Peptide technology for Herpes
Simplex Virus 2

• Gross profit margins maintained in competitive market

• Strategy being to grow through selective acquisitions

Regarding outlook, David Evans, Chairman, said:

'Trading in the current year remains flat and the rationale for seeking to grow
through acquisition is further underlined. The Board remains confident in that
stated objective and will update the markets accordingly.'

[guman] 30/5/2007 18:42

how careful of you not to say which year.

[gadg3t] 18/5/2007 12:44

Never know may even go up ! end of June may be !!

[the mullah] 17/5/2007 15:15

Yes, down.

[guman] 10/5/2007 15:42

is this ever going to move?

[gadg3t] 18/4/2007 19:18

Omega Diagnostics Group PLC
18 April 2007



Omega Diagnostics Group Plc (the 'Company')

Change of Accounting Reference Date



The board of the Company announce that the accounting reference date for the
Company has been changed to 31 March.



The Company will produce its next set of audited accounts to 31 March 2007 and
these will be posted to shareholders by 30 June 2007.



End

[gadg3t] 16/4/2007 17:25

Lets hope to see an up in the share price soon, but happy to hold and top up @1.25p

[rheiner] 16/4/2007 14:08

Omega Diagnostics Gr Omega Diagnostics gets European patent for specific herpes peptide sequence


LONDON (Thomson Financial) - Omega Diagnostics Group PLC said it has been
granted a European patent for the specific branched peptide sequence for Herpes
Simplex Virus 2 (HSV-2).
On Nov 6, Omega Diagnostics announced a European Patent has been granted in
respect of its branched peptide technology, which has been exclusively licensed
from the Medical Research Council.
[e-mail]
ukn/tc

[gadg3t] 04/4/2007 10:12

LONDON (AFX) - Medical diagnostics maker Omega Diagnostics Group PLC said it has appointed Fumouze Diagnostics, which is part of Sofibel SAS group, to act as its distributor for France.

No financial details were given.

The company said Fumouze will initially sell Omega's syphilis test product IMMUTREP-TPHA to infectious diseases and blood bank testing laboratories throughout France.

[gadg3t] 04/4/2007 10:07

Yes TopUP Time, I have e mailed Andrews to see if I can get an update/view on the company, will post his reply. the drop is possibly due to tax year end and this share is waiting to be noticed, they need to bump up profits but I do think we will see a tic up this year !